Evidence map›Paper›PMID 29177612›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2018

Evaluation of colistin stability in agar and comparison of four methods for MIC testing of colistin.

Agata Turlej-Rogacka, Basil Britto Xavier, Lore Janssens, Christine Lammens, Olympia Zarkotou, Spyros Pournaras, Herman Goossens, Surbhi Malhotra-Kumar

Open access · hybridAbstract readEvaluation Study
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Prevalence of Colistin-ResistantMicroorganisms · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Diagnostics (Basel, Switzerland) · 2021
    Article
  15. Article
  16. Article
  17. A Molecular Perspective on Colistin andDiagnostics (Basel, Switzerland) · 2021
    Review
  18. Evaluation ofNew microbes and new infections · 2021
    Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 3 countries.

Agata Turlej-RogackaLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Basil Britto XavierLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Lore JanssensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Christine LammensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Olympia ZarkotouDepartment of Microbiology, Medical School, University of Athens, Athens, Greece.
Spyros PournarasDepartment of Microbiology, Medical School, University of Athens, Athens, Greece.
Herman GoossensLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium.
Surbhi Malhotra-KumarLaboratory of Medical Microbiology, Vaccine & Infectious Disease Institute, University of Antwerp, Antwerp, Belgium. surbhi.malhotra@uantwerpen.be.ORCID http://orcid.org/0000-0001-8699-8905
University of Antwerp · BENational and Kapodistrian University of Athens · GR

Funding

EU-FP7 282512Universiteit Antwerpen BOF-DOCPRO 2012-27450
6 · The paper itself

Abstract

Susceptibility testing for colistin remains challenging primarily due to its inherent properties. We evaluated colistin stability in agar and reproducibility of colistin MICs obtained by agar dilution, broth macro- and micro-dilution and MIC gradient strips on 3-7 iterations of each method using clinical Klebsiella pneumoniae (susceptible-CS, and resistant-CR, n = 2 each), mcr-harboring Escherichia coli (n = 2), and reference strains E. coli ATCC25922 and Pseudomonas aeruginosa ATCC27853. MICs for reference strains were not in the given range using Etest and broth microdilution (ATCC25922, 0.125 and 4 μg/ml, respectively). MICs of CR-1 and CR-2, and of the mcr-harboring E. coli showed high concordance between agar and broth dilution varying up to one 2-fold dilution. However, remarkable variations were observed on broth dilution with CS-1 and CS-2 (MIC range 0.25-32 and 0.5-64 μg/ml, respectively); whereas for agar dilution the MIC for both CS strains was 0.5 μg/ml in all the runs. MICs obtained by MIC gradient strips were lower than those obtained by dilution methods (1-2 dilutions for CS and mcr strains, and up to five dilutions for CR strains). To confirm uniform distribution of colistin in agar, a single strain was spotted in five different regions of the same plate. All spots showed concordant growth with maximum one dilution difference. No effect on MIC was found due to storage of colistin-containing agar plates for 7 days at 4 °C. In our hands, agar dilution was superior in terms of reproducibility and robustness, compared to broth dilution methods, for colistin MIC determination.

Indexed as

AgarAnti-Bacterial AgentsColistinDisk Diffusion Antimicrobial TestsDrug Resistance, Multiple, BacterialEscherichia coliHumansKlebsiella pneumoniaePseudomonas aeruginosaAgarAnti-Bacterial AgentsColistinAgar dilutionBroth macrodilutionBroth microdilutionE-testEtestHeteroresistancePolymyxinsReproducibilitySkip wellsStabilitySusceptibility testing

Identifiers

PMID29177612
PMCPMC5780530
OpenAlexW2768524785

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.